- Home
- ASTC vs BCDA Comparison
ASTC vs BCDA Comparison
Compare ASTC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- BCDA
- Stock Information
- Founded
- ASTC 1984
- BCDA N/A
- Country
- ASTC United States
- BCDA United States
- Employees
- ASTC N/A
- BCDA N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- ASTC Industrials
- BCDA Health Care
- Exchange
- ASTC Nasdaq
- BCDA Nasdaq
- Market Cap
- ASTC 11.2M
- BCDA 11.5M
- IPO Year
- ASTC 1995
- BCDA N/A
- Fundamental
- Price
- ASTC $6.57
- BCDA $2.31
- Analyst Decision
- ASTC
- BCDA Strong Buy
- Analyst Count
- ASTC 0
- BCDA 1
- Target Price
- ASTC N/A
- BCDA $25.00
- AVG Volume (30 Days)
- ASTC 5.2K
- BCDA 69.0K
- Earning Date
- ASTC 02-14-2025
- BCDA 03-26-2025
- Dividend Yield
- ASTC N/A
- BCDA N/A
- EPS Growth
- ASTC N/A
- BCDA N/A
- EPS
- ASTC N/A
- BCDA N/A
- Revenue
- ASTC $419,000.00
- BCDA $71,000.00
- Revenue This Year
- ASTC N/A
- BCDA N/A
- Revenue Next Year
- ASTC N/A
- BCDA N/A
- P/E Ratio
- ASTC N/A
- BCDA N/A
- Revenue Growth
- ASTC N/A
- BCDA N/A
- 52 Week Low
- ASTC $6.12
- BCDA $1.63
- 52 Week High
- ASTC $12.29
- BCDA $8.85
- Technical
- Relative Strength Index (RSI)
- ASTC 46.09
- BCDA 45.73
- Support Level
- ASTC $6.25
- BCDA $2.27
- Resistance Level
- ASTC $6.76
- BCDA $2.95
- Average True Range (ATR)
- ASTC 0.34
- BCDA 0.26
- MACD
- ASTC 0.00
- BCDA -0.02
- Stochastic Oscillator
- ASTC 40.91
- BCDA 22.89
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).